MAIA Biotechnology beat earnings expectations but saw stock fall; its lead cancer drug is in Phase II trials. MAIA Biotechnology beat earnings expectations but saw stock fall; its lead cancer drug is in Phase II trials.

MAIA Biotechnology, a cancer therapy-focused biotech firm, reported quarterly earnings of ($0.11) per share, beating analysts' expectations of ($0.32). MAIA Biotechnology, a cancer therapy-focused biotech firm, reported quarterly earnings of ($0.11) per share, beating analysts' expectations of ($0.32). اس کے باوجود، اس کا اسٹاک قیمت تقریباً $2.20 تک گر گئی۔ Despite this, its stock price fell to about $2.20. MAIA کا سربراہ مصنوعات، THIO، غیر چھوٹے خلیوں کے سانس کے کینسر کے لئے مرحلہ II کے تجربات میں ہے۔ MAIA's lead product, THIO, is in Phase II trials for non-small cell lung cancer. کمپنی کے مینیجر نے حال ہی میں حصص خریدے ہیں، جس سے کمپنی کے حصص کی مجموعی ملکیت 36.98% تک پہنچ گئی ہے۔ The company's director recently bought shares, increasing insider ownership to 36.98% of the company's stock.